Discovery of ligands by a combination of computational and NMR-based screening: RNA as an example target

Methods in Enzymology

Volumn 394, Issue , 2005, Pages 571-587

  Mayer, Moriz ^a   James, Thomas L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; LIGAND; ORGANIC COMPOUND; PYRIMIDINE; RNA; UNCLASSIFIED DRUG; WATER;

ARTICLE; BINDING AFFINITY; BINDING SITE; CHEMICAL MODIFICATION; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG BINDING; DRUG STRUCTURE; DRUG TARGETING; EXPERIMENT; GENE EXPRESSION; LIGAND BINDING; MOLECULE; MONITORING; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RNA ANALYSIS; RNA BINDING; RNA CONFORMATION; RNA STRUCTURE; SCREENING; SENSITIVITY ANALYSIS; SIGNAL NOISE RATIO; SOLUBILITY; SPECTROSCOPY; STRUCTURE ANALYSIS; THREE DIMENSIONAL IMAGING; VALIDATION PROCESS;

EID: 16244416482     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(05)94024-X     Document Type: Article

References (65)

1. Abagyan R., Totrov M. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J. Mol. Biol. 235:1994;983-1002
2. Abagyan R.A., Totrov M.M., Kuznetsov D.N. ICM - a new method for protein modeling and design - applications to docking and structure prediction from the distorted native conformation. J. Comp. Chem. 15:1994;488-506
3. Bajorath F. Integration of virtual and high-throughput screening. Nat. Rev. Drug Discov. 1:2002;882-894
4. Bhunia A., Jayalakshmi V., Benie A.J., Schuster O., Kelm S., Rama Krishna N., Peters T. Saturation transfer difference NMR and computational modeling of a sialoadhesin-sialyl lactose complex. Carbohydr. Res. 339:2004;259-267
5. Bissantz C., Folkers G., Rognan D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J. Med. Chem. 43:2000;4759-4767
6. Chen Q., Shafer R.H., Kuntz I.D. Structure-based discovery of ligands targeted to the RNA double helix. Biochemistry. 36:1997;11402-11407
7. Colca J.R., McDonald W.G., Waldon D.J., Thomasco L.M., Gadwood R.C., Lund E.T., Cavey G.S., Mathews W.R., Adams L.D., Cecil E.T., Pearson J.D., Bock J.H., Mott J.E., Shinabarger D.L., Xiong L., Mankin A.S. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J. Biol. Chem. 278:2003;21972-21979
8. Coles M., Heller M., Kelssler H. NMR-based screening technologies. Drug Discov. Today. 8:2003;803-810
9. Crowley P.B., Rabe K.S., Worrall J.A., Canters G.W., Ubbink M. The ternary complex of cytochrome F and cytochrome C: Identification of a second binding site and competition for plastocyanin binding. Chembiochem. 3:2002;526-533
10. Dalvit C., Pevarello P., Tato M., Veronesi M., Vulpetti A., Sundstrom M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR. 18:2000;65-68
11. Dalvit C., Fogliatto G., Stewart A., Veronesi M., Stockman B. Waterlogsy as a method for primary NMR screening: Practical aspects and range of applicability. J. Biomol. NMR. 21:2001;349-359
12. Dalvit C., Ardini E., Flocco M., Fogliatto G.P., Mongelli N., Veronesi M. A general NMR method for rapid, efficient, and reliable biochemical screening. J. Am. Chem. Soc. 125:2003;14620-14625
13. Davis A.M., Teague S.J., Kleywegt G.J. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew. Chem. Int. Ed. 42:2003;2718-2736
14. Davis B., Afshar M., Varani G., Murchie A.I.H., Karn J., Lentzen G., Drysdale M.J., Bower J., Potter A.J., Starkey I.D., Swarbrick T.M., Aboul-Ela F. Rational design of inhibitors of HIV-1 TAR RNA through the stabilisation of electrostatic "hot spots." J. Mol. Biol. 336:2004;343-356
15. Feeney J., Roberts G.C., Thomson J.W., King R.W., Griffiths D.V., Burgen A.S. Proton nuclear magnetic resonance studies of the effects of ligand binding on tryptophan residues of selectively deuterated dihydrofolate reductase from Lactobacillus casei. Biochemistry. 19:1980;2316-2321
16. Fejzo J., Lepre C.A., Peng J.W., Bemis G.W., Ajay Murcko, M. A., Moore J.M. The shapes strategy: An NMR-based approach for lead generation in drug discovery. Chem. Biol. 6:1999;755-769
17. Filikov A.V., Mohan V., Vickers T.A., Griffey R.H., Cook P.D., Abagyan R.A., James T.L. Identification of ligands for RNA targets via structure-based virtual screening: HIV-1 TAR. J. Comp. Aided Mol. Des. 14:2000;593-610
18. Foloppe N., Chen I.J., Davis B., Hold A., Morley D., Howes R. A structure-based strategy to identify new molecular scaffolds targeting the bacterial ribosomal A-site. Bioorg. Med. Chem. 12:2004;935-947
19. Fourmy D., Recht M.I., Blanchard S.C., Puglisi J.D. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science. 274:1996;1367-1371
20. Fourmy D., Yoshizawa S., Puglisi J.D. Paromomycin binding induces a local conformational change in the A-site of 16 S rRNA. J. Mol. Biol. 277:1998;333-345
21. Gallego J., Varani G. Targeting RNA with small-molecule drugs: Therapeutic promise and chemical challenges. Acc. Chem. Res. 34:2001;836-843
22. Griffey R.H., Hofstadler S.A., Sannes-Lowery K.A., Ecker D.J., Crooke S.T. Determinants of aminoglycoside-binding specificity for rRNA by using mass spectrometry. Proc. Natl. Acad. Sci. USA. 96:1999;10129-10133
23. Hajduk P.J., Burns D.J. Integration of NMR and high-throughput screening. Comb. Chem. High Throughput Screen. 5:2002;613-621
24. Hajduk P.J., Bures M., Praestgaard J., Fesik S.W. Privileged molecules for protein binding identified from NMR-based screening. J. Med. Chem. 43:2000;3443-3447
25. Hajduk P.J., Betz S.F., Mack J., Ruan X., Towne D.L., Lerner C.G., Beutel B.A., Fesik S.W. A strategy for high-throughput assay development using leads derived from nuclear magnetic resonance-based screening. J. Biomol. Screen. 7:2002;429-432
26. Hermann T. Strategies for the design of drugs targeting RNA and RNA-protein complexes. Angew. Chem. Int. Ed. 39:2000;1891-1905
27. Hermann T. Rational ligand design for RNA: The role of static structure and conformational flexibility in target recognition. Biochimie. 84:2002;869-875
28. Hermann T. Chemical and functional diversity of small molecule ligands for RNA. Biopolymers. 70:2003;4-18
29. Hwang S., Tamilarasu N., Ryan K., Huq I., Richter S., Still W.C., Rana T.M. Inhibition of gene expression in human cells through small molecule-RNA interactions. Proc. Natl. Acad. Sci. USA. 96:1999;12997-13002
30. Jayalakshmi V., Rama Krishna N. Corcema refinement of the bound ligand conformation within the protein binding pocket in reversibly forming weak complexes using STD-NMR intensities. J. Magn. Reson. 168:2004;36-45
31. Johnson E.C., Feher V.A., Peng J.W., Moore J.M., Williamson J.R. Application of NMR shapes screening to an RNA target. J. Am. Chem. Soc. 125:2003;15724-15725
32. Jones G., Willett P., Glen R.C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 245:1995;43-53
33. Kick E.K., Roe D.C., Skillman A.G., Liu G., Ewing T.J.A., Sun Y., Kuntz I.D., Ellman J.A. Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D. Chem. Biol. 4:1997;297-307
34. Kramer B., Rarey M., Lengauer T. Evaluation of the flexx incremental construction algorithm for protein-ligand docking. Proteins. 37:1999;228-241
35. Leone M., Rodriguez-Mias R.A., Pellecchia M. Selective incorporation of 19F-labeled Trp side chains for NMR-spectroscopy-based ligand-protein interaction studies. Chembiochem. 4:2003;649-650
36. Lepre C.A. Library design for NMR-based screening. Drug Discov. Today. 6:2001;133-140
37. Lepre C.A., Peng J., Fejzo J., Abdul-Manan N., Pocas J., Jacobs M., Xie X., Moore J.M. Applications of shapes screening in drug discovery. Comb. Chem. High Throughput Screen. 5:2002;583-590
38. Lian L.Y., Barsukov I.L., Sutcliffe M.J., Sze K.H., Roberts G.C. Protein-ligand interactions: Exchange processes and determination of ligand conformation and protein-ligand contacts. Methods Enzymol. 239:1994;657-700
39. Lind K.E., Du Z., Fujinaga K., Peterlin B.M., James T.L. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. Chem. Biol. 9:2002;185-193
40. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 44:2000;235-249
41. Luedtke N.W., Tor Y. Fluorescence-based methods for evaluating the RNA affinity and specificity of HIV-1 rev-RRE inhibitors. Biopolymers. 70:2003;103-119
42. Lynch S.R., Recht M.I., Puglisi J.D. Biochemical and nuclear magnetic resonance studies of aminoglycoside-RNA complexes. Methods Enzymol. 317:2000;240-261
43. Lynch S.R., Gonzalez R.L., Puglisi J.D. Comparison of X-ray crystal structure of the 30s subunit-antibiotic complex with NMR structure of decoding site oligonucleotide-paromomycin complex. Structure (Camb.). 11:2003;43-53
44. Lyne P.D. Structure-based virtual screening: An overview. Drug Discov. Today. 7:2002;1047-1055
45. Marchioro C., Davalli S., Provera S., Heller M., Ross A., Senn H. Zerbe O. "BioNMR in Drug Research" 2002;321-340 Wiley-VCH, Weinheim, Germany
46. Mayer M., James T.L. Detecting ligand binding to a small RNA target via saturation transfer difference NMR experiments in D(2)O and H(2)O. J. Am. Chem. Soc. 124:2002;13376-13377
47. Mayer M., James T.L. NMR-based characterization of phenothiazines as a RNA binding scaffold. J. Am. Chem. Soc. 126:2004;4453-4460
48. Mayer M., Meyer B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. 38:1999;1784-1788
49. Mei H.-Y., Cui M., Heldsinger A., Lemrow S.M., Loo J.A., Sannes-Lowery K.A., Sharmeen L., Czarnik A.W. Inhibitors of protein-RNA complexation that target the RNA: Specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules. Biochemistry. 37:1998;14204-14212
50. Meyer B., Peters T. NMR Spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew. Chem. Int. Ed. 42:2003;864-890
51. Mirau P.A., Shafer R.H., James T.L. Binding of 5-fluorotryptamine to polynucleotides as a model for protein-nucleic acid interactions: Fluorine-19 nuclear magnetic resonance, absorption, and fluorescence studies. Biochemistry. 21:1982;615-620
52. Moore J., Abdul-Manan N., Fejzo J., Jacobs M., Lepre C., Peng J., Xie X. Leveraging structural approaches: Applications of NMR-based screening and X-ray crystallography for inhibitor design. J. Synchrotron Radiat. 11:2004;97-100
53. Murchie A.I.H., Davis B., Isel C., Afshar M., Drysdale M.J., Bower J., Potter A.J., Starkey I.D., Swarbrick T.M., Mirza S., Prescott C.D., Vaglio P., Aboul-ela F., Karn J. Structure-based drug design targeting an inactive RNA conformation: Exploiting the flexibility of HIV-1 TAR RNA. J. Mol. Biol. 336:2004;625-638
54. Olejniczak M., Gdaniec Z., Fischer A., Grabarkiewicz T., Bielecki L., Adamiak R.W. The bulge region of HIV-1 TAR RNA binds metal ions in solution. Nucleic Acids Res. 30:2002;4241-4249
55. Peng J.W., Lepre C.A., Fejzo J., Abdul-Manan N., Moore J.M. Nuclear magnetic resonance-based approaches for lead generation in drug discovery. Methods Enzymol. 338:2001;202-230
56. Roberts G.C. Zerbe O. "BioNMR in Drug Research" 2002;309-319 Wiley-VCH, Weinheim, Germany
57. Rudisser S., Jahnke W. NMR and in silico screening. Comb. Chem. High Throughput Screen. 5:2002;591-603
58. Stahl M., Rarey M. Detailed analysis of scoring functions for virtual screening. J. Med. Chem. 44:2001;1035-1042
59. Swayze E.E., Jefferson E.A., Sannes-Lowery K.A., Blyn L.B., Risen L.M., Arakawa S., Osgood S.A., Hofstadler S.A., Griffey R.H. SAR by MS: A ligand based technique for drug lead discovery against structured RNA targets. J. Med. Chem. 45:2002;3816-3819
60. Valler M.J., Green D. Diversity screening versus focussed screening in drug discovery. Drug Discov. Today. 5:2000;286-293
61. van Dongen M., Weigelt J., Uppenberg J., Schultz J., Wikstrom M. Structure-based screening and design in drug discovery. Drug Discov. Today. 7:2002;471-478
62. Wei B.Q., Weaver L.H., Ferrari A.M., Matthews B.W., Shoichet B.K. Testing a flexible-receptor docking algorithm in a model binding site. J. Mol. Biol. 337:2004;1161-1182
63. Wimberly B.T., Brodersen D.E., Clemons W.M., Morgan-Warren R.J., Carter A.P., Vonrhein C., Hartsch T., Ramakrishnan V. Structure of the 30S ribosomal subunit. Nature. 407:2000;327-339
64. Wyss D.F., McCoy M.A., Senior M.M. NMR-based approaches for lead discovery. Curr. Opin. Drug Discov. Dev. 5:2002;630-647
65. Yu L., Oost T.K., Schkeryantz J.M., Yang J., Janowick D., Fesik S.W. Discovery of aminoglycoside mimetics by NMR-based screening of Escherichia coli A-site RNA. J. Am. Chem. Soc. 125:2003;4444-4450